Open AccessDurable response to programmed death-1 (PD-1) blockade in a metastatic gastric cancer patient with mismatch repair deficiency and microsatellite instability
Author(s) -
Tsan-Ming Wu,
Emily HanChung Hsiue,
ChangTsu Yuan,
Li Hui Tseng,
ChiaChi Lin,
KunHuei Yeh
Publication year - 2017
Publication title -
journal of cancer research and practice
Language(s) - English
Resource type - Journals
eISSN - 2589-0425
pISSN - 2311-3006
DOI - 10.1016/j.jcrpr.2016.11.001
Subject(s) - medicine , microsatellite instability , pembrolizumab , blockade , cancer , colorectal cancer , dna mismatch repair , oncology , pd l1 , refractory (planetary science) , immunotherapy , microsatellite , receptor , biochemistry , allele , chemistry , physics , astrobiology , gene
Mismatch repair deficiency (dMMR) or microsatellite instability (MSI) has been reported as a predictive biomarker for responses to programmed death-1 (PD-1) blockade in metastatic colorectal cancer. A high response rate to anti-PD-1 therapy was observed in other cancer types with MSI. We report a chemotherapy-refractory metastatic gastric cancer patient with dMMR and MSI who responded remarkably well to pembrolizumab, a PD-1 monoclonal antibody. The satisfactory objective response has lasted for more than 24 months as of this report